Systemic Juvenile Idiopathic Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major systemic juvenile idiopathic arthritis markets reached a value of US$ 900 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,250 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.
The systemic juvenile idiopathic arthritis market has been comprehensively analyzed in IMARC's new report titled "Systemic Juvenile Idiopathic Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Systemic juvenile idiopathic arthritis refers to a rare, chronic, autoimmune disease that affects children. This condition causes inflammation in one or more joints as well as other organs in the body, such as the liver, spleen, lymph nodes, and heart. The severity of the illness can vary widely among individuals, with some experiencing only mild symptoms while others have severe signs and complications, like disability and eye problems. The most common indications of the ailment include persistent joint pain, stiffness, and swelling. In some cases, patients suffering from this illness may experience high fever, a rash on the trunk, swollen lymph nodes, enlarged liver and spleen, inflammation of the heart's muscular tissue, etc. The diagnosis of systemic juvenile idiopathic arthritis is made by a review of detailed clinical features, medical history, and laboratory studies. A healthcare provider may perform an echocardiogram, along with a chest X-ray and CT scan, which help to rule out other possible causes. Additionally, a skin biopsy is recommended for better evaluation of the rash.
The increasing cases of immune-mediated disorders, in which the body's innate defense system mistakenly attacks and damages healthy tissues, are primarily driving the systemic juvenile idiopathic arthritis market. Besides this, the widespread adoption of non-steroidal anti-inflammatory drugs, such as naproxen, ibuprofen, diclofenac, etc., for relieving symptoms like swelling and improving survival rates in patients is also augmenting the market growth. Furthermore, the escalating utilization of physiotherapy interventions to restore flexibility as well as build strength and endurance in stiff joints is acting as another significant growth-inducing factor. Additionally, multiple key players are making extensive investments in R&D activities to launch novel assistive devices that can improve function and reduce unnecessary stresses on inflamed joints. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of biologic medications, including anakinra and canakinumab, since they target specific inflammatory molecules to minimize indications and significantly enhance the quality of life in patients, is expected to drive the systemic juvenile idiopathic arthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the systemic juvenile idiopathic arthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for systemic juvenile idiopathic arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the systemic juvenile idiopathic arthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the systemic juvenile idiopathic arthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the systemic juvenile idiopathic arthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current systemic juvenile idiopathic arthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the systemic juvenile idiopathic arthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the systemic juvenile idiopathic arthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the systemic juvenile idiopathic arthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with systemic juvenile idiopathic arthritis across the seven major markets?
What is the size of the systemic juvenile idiopathic arthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of systemic juvenile idiopathic arthritis?
What will be the growth rate of patients across the seven major markets?
Systemic Juvenile Idiopathic Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for systemic juvenile idiopathic arthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the systemic juvenile idiopathic arthritis market?
What are the key regulatory events related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by status related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by phase related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by route of administration related to the systemic juvenile idiopathic arthritis market?
The systemic juvenile idiopathic arthritis market has been comprehensively analyzed in IMARC's new report titled "Systemic Juvenile Idiopathic Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Systemic juvenile idiopathic arthritis refers to a rare, chronic, autoimmune disease that affects children. This condition causes inflammation in one or more joints as well as other organs in the body, such as the liver, spleen, lymph nodes, and heart. The severity of the illness can vary widely among individuals, with some experiencing only mild symptoms while others have severe signs and complications, like disability and eye problems. The most common indications of the ailment include persistent joint pain, stiffness, and swelling. In some cases, patients suffering from this illness may experience high fever, a rash on the trunk, swollen lymph nodes, enlarged liver and spleen, inflammation of the heart's muscular tissue, etc. The diagnosis of systemic juvenile idiopathic arthritis is made by a review of detailed clinical features, medical history, and laboratory studies. A healthcare provider may perform an echocardiogram, along with a chest X-ray and CT scan, which help to rule out other possible causes. Additionally, a skin biopsy is recommended for better evaluation of the rash.
The increasing cases of immune-mediated disorders, in which the body's innate defense system mistakenly attacks and damages healthy tissues, are primarily driving the systemic juvenile idiopathic arthritis market. Besides this, the widespread adoption of non-steroidal anti-inflammatory drugs, such as naproxen, ibuprofen, diclofenac, etc., for relieving symptoms like swelling and improving survival rates in patients is also augmenting the market growth. Furthermore, the escalating utilization of physiotherapy interventions to restore flexibility as well as build strength and endurance in stiff joints is acting as another significant growth-inducing factor. Additionally, multiple key players are making extensive investments in R&D activities to launch novel assistive devices that can improve function and reduce unnecessary stresses on inflamed joints. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of biologic medications, including anakinra and canakinumab, since they target specific inflammatory molecules to minimize indications and significantly enhance the quality of life in patients, is expected to drive the systemic juvenile idiopathic arthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the systemic juvenile idiopathic arthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for systemic juvenile idiopathic arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the systemic juvenile idiopathic arthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the systemic juvenile idiopathic arthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the systemic juvenile idiopathic arthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current systemic juvenile idiopathic arthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the systemic juvenile idiopathic arthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the systemic juvenile idiopathic arthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the systemic juvenile idiopathic arthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with systemic juvenile idiopathic arthritis across the seven major markets?
What is the size of the systemic juvenile idiopathic arthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of systemic juvenile idiopathic arthritis?
What will be the growth rate of patients across the seven major markets?
Systemic Juvenile Idiopathic Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for systemic juvenile idiopathic arthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the systemic juvenile idiopathic arthritis market?
What are the key regulatory events related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by status related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by phase related to the systemic juvenile idiopathic arthritis market?
What is the structure of clinical trial landscape by route of administration related to the systemic juvenile idiopathic arthritis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - UNMET NEEDS
10 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - MARKETED PRODUCTS
11.1 List of Systemic Juvenile Idiopathic Arthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Actemra (Tocilizumab) - Chugai Pharmaceutical/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ilaris (Canakinumab) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - PIPELINE DRUGS
12.1 List of Systemic Juvenile Idiopathic Arthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Anakinra - Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Baricitinib - Eli Lilly and Company/Incyte Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
16 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - UNMET NEEDS
10 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - MARKETED PRODUCTS
11.1 List of Systemic Juvenile Idiopathic Arthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Actemra (Tocilizumab) - Chugai Pharmaceutical/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ilaris (Canakinumab) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - PIPELINE DRUGS
12.1 List of Systemic Juvenile Idiopathic Arthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Anakinra - Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Baricitinib - Eli Lilly and Company/Incyte Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Systemic Juvenile Idiopathic Arthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Systemic Juvenile Idiopathic Arthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Systemic Juvenile Idiopathic Arthritis - Access and Reimbursement Overview
16 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
